Kura Oncology, Inc. - Common Stock — Cash Flow (NASDAQ:KURA) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -69.83 M-104.55 M-110.06 M-124.82 M134.32 M-64.06 M -111.76 M Cash from investing activities -99.94 M-126.83 M32.63 M15.56 M-101.59 M-13.1 M 97.35 M Cash from financing activities 469.33 M-3.44 M38.56 M94.78 M154.42 M1.79 M 2.7 M Free cash flow -69.83 M-104.55 M-110.06 M-124.82 M134.32 M-70.7 M -117.43 M

News

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

Kura Oncology: 'Strong Buy' Ziftomenib AML Expansions Could Boost KOMZIFTI's Prospects

Company News for Aug 26, 2026

The $1.24 Billion Reason Why Kura Oncology Stock Is Up Today

Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?

Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?

Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript

Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates